Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Mar 11

Thu, 12 Mar 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260312/26148567.html

Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Mar 11

Thu, 12 Mar 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260312/26148567.html

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Announces February 28, 2026 Assets Under Management

Wed, 11 Mar 2026 16:05:00 -0400

NASHVILLE, Tenn., March 11, 2026 /PRNewswire/ -- AllianceBernstein L.P. ("AB") and AllianceBernstein Holding L.P. ("AB Holding") (NYSE: AB) today announced that preliminary assets under management increased to $880 billion during February 2026 from $875 billion at the end of January. The 0.6% increase in month-end AUM was driven by market appreciation, partially offset by modest net outflows. By channel, net inflows in Private Wealth and Institutional were offset by net outflows in Retail during February.

AllianceBernstein

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

Tue, 24 Feb 2026 12:02:00 -0400

PRESS RELEASE

AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO INFLAMATORY MICROGLIA, WHICH ARE TARGETED BY MASITINIB

THIS BIOMARKER IS ALSO APPLICABLE TO PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS AND ALZHEIMER DISEASE

THIS BIOMARKER CAN BE STRATEGIC TO DETERMINE WHICH PATIENTS RESPOND TO TREATMENT AND POTENTIALLY INCREASE CHANCE OF REGISTRATION IN NEURODEGENERATIVE DISEASES

Paris, February 24, 2026, 6pm CET

AB Science SA (Euronext - FR0010557264 - AB) announced

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

Tue, 24 Feb 2026 12:02:00 -0400

PRESS RELEASE

AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO INFLAMATORY MICROGLIA, WHICH ARE TARGETED BY MASITINIB

THIS BIOMARKER IS ALSO APPLICABLE TO PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS AND ALZHEIMER DISEASE

THIS BIOMARKER CAN BE STRATEGIC TO DETERMINE WHICH PATIENTS RESPOND TO TREATMENT AND POTENTIALLY INCREASE CHANCE OF REGISTRATION IN NEURODEGENERATIVE DISEASES

Paris, February 24, 2026, 6pm CET

AB Science SA (Euronext - FR0010557264 - AB) announced

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

Tue, 24 Feb 2026 12:02:00 -0400

PRESS RELEASE

AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO INFLAMATORY MICROGLIA, WHICH ARE TARGETED BY MASITINIB

THIS BIOMARKER IS ALSO APPLICABLE TO PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS AND ALZHEIMER DISEASE

THIS BIOMARKER CAN BE STRATEGIC TO DETERMINE WHICH PATIENTS RESPOND TO TREATMENT AND POTENTIALLY INCREASE CHANCE OF REGISTRATION IN NEURODEGENERATIVE DISEASES

Paris, February 24, 2026, 6pm CET

AB Science SA (Euronext - FR0010557264 - AB) announced

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

Tue, 24 Feb 2026 12:02:00 -0400

PRESS RELEASE

AB SCIENCE ANNOUNCES THE IDENTIFICATION OF A PLASMA BIOMARKER THAT INDICATES THE ACTIVITY OF MASITINIB IN TREATING AMYOTROPHIC LATERAL SCLEROSIS, AND THAT IS CAPABLE OF IDENTIFYING PATIENTS WITH PRO INFLAMATORY MICROGLIA, WHICH ARE TARGETED BY MASITINIB

THIS BIOMARKER IS ALSO APPLICABLE TO PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS AND ALZHEIMER DISEASE

THIS BIOMARKER CAN BE STRATEGIC TO DETERMINE WHICH PATIENTS RESPOND TO TREATMENT AND POTENTIALLY INCREASE CHANCE OF REGISTRATION IN NEURODEGENERATIVE DISEASES

Paris, February 24, 2026, 6pm CET

AB Science SA (Euronext - FR0010557264 - AB) announced

Increasing unusual option volume: AB PBRA CMI GLBE SHEL WTI AZN

Fri, 20 Feb 2026 05:30:14 -0400

Increasing unusual option volume: AB PBRA CMI GLBE SHEL WTI AZN

Form 4 ALLIANCEBERNSTEIN HOLDIN For: Feb 18 Filed by: BERNSTEIN SETH P

Thu, 19 Feb 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260219/26029801.html

Form 4 ALLIANCEBERNSTEIN HOLDIN For: Feb 18 Filed by: BERNSTEIN SETH P

Thu, 19 Feb 2026 16:07:00 -0400
si-local-file:///var/storage/secattach/20260219/26029801.html

Form 144 ALLIANCEBERNSTEIN HOLDIN Filed by: BERNSTEIN SETH P

Wed, 18 Feb 2026 10:31:00 -0400
si-local-file:///var/storage/secattach/20260218/26019644.html

Form 144 ALLIANCEBERNSTEIN HOLDIN Filed by: BERNSTEIN SETH P

Wed, 18 Feb 2026 10:31:00 -0400
si-local-file:///var/storage/secattach/20260218/26019644.html

Form 144 ALLIANCEBERNSTEIN HOLDIN Filed by: BERNSTEIN SETH P

Wed, 18 Feb 2026 10:31:00 -0400
si-local-file:///var/storage/secattach/20260218/26019645.html

Form 144 ALLIANCEBERNSTEIN HOLDIN Filed by: BERNSTEIN SETH P

Wed, 18 Feb 2026 10:31:00 -0400
si-local-file:///var/storage/secattach/20260218/26019645.html

StreetInsider.com News Articles

Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Mar 11

Form 8-K ALLIANCEBERNSTEIN HOLDIN For: Mar 11

AB Announces February 28, 2026 Assets Under Management

AB Announces February 28, 2026 Assets Under Management

AB Announces February 28, 2026 Assets Under Management

AB Announces February 28, 2026 Assets Under Management

AB Announces February 28, 2026 Assets Under Management

AB Announces February 28, 2026 Assets Under Management

AB Announces February 28, 2026 Assets Under Management

AB Announces February 28, 2026 Assets Under Management

AB Announces February 28, 2026 Assets Under Management

AB Announces February 28, 2026 Assets Under Management

AB Announces February 28, 2026 Assets Under Management

AB Announces February 28, 2026 Assets Under Management

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

AB Science announces the identification of a plasma biomarker that indicates the activity of masitinib in treating ALS

Increasing unusual option volume: AB PBRA CMI GLBE SHEL WTI AZN

Form 4 ALLIANCEBERNSTEIN HOLDIN For: Feb 18 Filed by: BERNSTEIN SETH P

Form 4 ALLIANCEBERNSTEIN HOLDIN For: Feb 18 Filed by: BERNSTEIN SETH P

Form 144 ALLIANCEBERNSTEIN HOLDIN Filed by: BERNSTEIN SETH P

Form 144 ALLIANCEBERNSTEIN HOLDIN Filed by: BERNSTEIN SETH P

Form 144 ALLIANCEBERNSTEIN HOLDIN Filed by: BERNSTEIN SETH P

Form 144 ALLIANCEBERNSTEIN HOLDIN Filed by: BERNSTEIN SETH P